我国基本药物省级增补目录与WHO示范目录的比较  

Comparative analysis between provincial supplementary essential medicines lists and the WHO 2011 model list

作　　者：王丽洁[1] 徐文娟[1] 陈文[1] 蒋虹丽[1] 张璐莹[1] 

机构地区：[1]复旦大学公共卫生学院,上海200032

出　　处：《中国卫生政策研究》2012年第7期26-30,共5页Chinese Journal of Health Policy

基　　金：卫生部统计信息中心资助课题

摘　　要：目的:将我国22个基本药物省级增补目录与WHO2011版基本药物示范目录进行对比分析,为完善国家基本药物目录和省级增补目录提供决策参考。方法:采用WHO官网公开的WHO1977—2011基本药物示范目录汇总表录入增补药品,进行矩阵表分析。结果:各地增补目录遴选标准主要涉及治疗疾病、遴选范围及药品附加条件等。22个基本药物省级增补目录共新增品种591种,其中87种被WHO示范目录收录,未被示范目录收录药品中部分为WHO删除品种;另对66种国家基本药物品种增加了新剂型;有57种药品被50%以上的省级增补目录共同收录。结论与建议:省级增补目录遴选品种数量与WHO目录存在差异可以作为目录调整循证依据,增补目录遴选标准有待完善,目录遴选应向循证方式转变。Objectives： To comparatively analyze twenty-two selected China provincial supplementary essential medicines lists （PEML） with the WHO 2011 model list for revision of national and provincial lists. Method： Matc- hing PEML medicines into the spreadsheet of historical master list （ 1977--2011 ） available on WHO website. Re- sults ： The consideration of PEML selection includes target diseases, fixed selection scope, and medicines related re- quirements. Totally 591 western medicines were supplemented to the national list and other 66 were national ones with additional forms. 87 products are both on the WHO and provincial lists while others are not recommended by WHO, including those already deleted from the model list. The listing frequency of 57 medicines is above 50% in 22 provinces. Conclusion and recommendation： There is difference between provincial and WHO model lists, which could be taken as the benchmark evidence for lists revision. The selection criteria should be specified and the method needs to be transferred from expert based to evidence based.

关 键 词：基本药物 省级增补目录 WHO示范目录 比较研究 

分 类 号：R951[医药卫生—药学]